Purpose: To describe the case of 49-year-old woman with a history of rheumatoid arthritis on hydroxychloroquine (HCQ) therapy, who presented with findings of HCQ retinopathy on optical coherence tomography (OCT). Methods: Evaluation included clinical examination with multimodal imaging findings on spectral domain (SD)-OCT, en face OCT, and multifocal electroretinogram (mfERG). Results: The patient had nonspecific visual symptoms and an unremarkable funduscopic examination. Humphrey visual fields, fundus autofluorescence, mfERG, SD-OCT, and en face structural OCT, however, suggested HCQ retinal toxicity. Conclusions: This case demonstrates that the findings of HCQ retinopathy on en face structural OCT are analogous to those identified by current imaging modalities used for the screening and diagnosis of HCQ toxicity. En face structural OCT may be useful in the detection of HCQ-induced retinal toxicity.
Introduction
Hydroxychloroquine (HCQ), an antimalarial drug used to treat autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, may cause retinopathy. 1, 2 Although prolonged HCQ use carries a low risk of systemic and retinal toxicity, when retinopathy does occur, it can lead to irreversible vision loss by damaging photoreceptors and retinal pigment epithelium. 2, 3 The primary screening tests, based on current guidelines, are spectral domain optical coherence tomography (SD-OCT) and automated visual fields; multifocal electroretinogram (mfERG) and fundus autofluorescence (FAF) are also frequently used. 2 Therefore, retinal imaging plays a crucial role in screening and diagnosing HCQ toxicity. 2, 4 We present the case of a 49-year-old female, weighing 89 kg, with a history of rheumatoid arthritis controlled with HCQ 200 mg daily (2.25 mg/kg) for 6 years, who had minimal fundus findings but significant changes seen on imaging.
Methods
Upon presentation for evaluation of the retina, the following were performed: visual acuity testing, confrontational visual fields, intraocular pressures measurements, dilated fundus examination, fluorescein angiography, near infrared FAF, Humphrey 10-2 visual field (HVF) testing, SD-OCT (Spectralis; Heidelberg Engineering, Germany), en face structural and angiography SD-OCT (AngioVue; Optovue, Fremont, California), and multifocal electroretinogram.
Results
The patient had been followed by a comprehensive ophthalmologist who had performed visual field testing annually over the last 2 years and not detected changes consistent with HCQ toxicity. On examination, her best-corrected visual acuity was 20/20 in the right eye (OD) and 20/25 in the left eye (OS). Pupils, confrontational visual fields, and intraocular pressures were normal. Dilated fundus examination showed prominent choroidal vessels throughout the blonde fundus bilaterally ( Figure 1A (Figure 4) . The SD-OCTA (AngioVue; Optovue) revealed normal retinal vessels in the superficial and deep retinal capillary plexus. However, en face structural SD-OCT imaging showed an increased reflectivity in the deep retina ( Figures 5D and 6D ) and outer retina ( Figure 5F ) of both eyes. The findings were discussed with the patient's rheumatologist and discontinuation of HCQ was recommended. 
Conclusions
In this case report, we present a white Hispanic patient on HCQ therapy without bull's eye maculopathy but significant findings of HCQ toxicity on HVF, FAF, mfERG, and en face structural OCT. Melles and Marmor estimate that HCQ retinal toxicity has an overall prevalence of 7.5% after 5 years of the drug usage. 3 Although the dose considered to be a risk factor for HCQ retinal toxicity exceeds 5.0 mg/kg/d, our case demonstrates that it can be seen even in patients on weightappropriate, or "nontoxic," doses. 2 The classic clinical sign of HCQ toxicity is the "bull's eye maculopathy," a targetoid appearance of the macula due to the presence of pigmentary changes. 2 However, on dilated fundus examination, this finding may not be present until advanced stages of toxicity. 5 Furthermore, as seen in our case, bull's eye maculopathy may not develop even in the setting of severe HCQ toxicity.
Early detection of HCQ retinopathy is crucial to prevent visual loss because the toxic effects on the retina may be irreversible and continue to progress after the medication has been discontinued. 5 Patients with early HCQ retinopathy can present with difficulty reading, scotomas in the visual field, night blindness, or changes in color vision, yet some have no visual symptoms at all. 2, 5 Owing to the fact that initial HCQ retinopathy can present in asymptomatic patients, the American Academy of Ophthalmology's screening recommendations (03/2016) include automated visual fields and SD-OCT as well as mfERG or FAF. 2 In our patient, we identified an increased reflectivity on the deep retinal layer and on the outer retinal layer. The outer retinal layer increased reflectivity could be due to the photoreceptor inner-outer segment/ellipsoid zone loss observed on regular SD-OCT. Kam et al previously demonstrated that in a patient with HCQ toxicity, OCTangiography (OCTA) showed reduced density of the parafoveal outer retinal vasculature and preservation of the central foveal vasculature. 6 In our patient, the OCTA findings were unremarkable. This could be due to fact that our patient had an earlier stage of HCQ retinopathy in comparison to Kam et al study. 6 The en face structural OCT findings identified in this case are analogous to what is identified with HVF, FAF, and B-scan OCT-the currently recommended modalities for detecting HCQ retinopathy. 6 Although further studies are needed, multimodal imaging can be even more critical in identifying toxicity in cases of myopic and lightly pigmented fundi such as this one. Furthermore, these early findings suggest that there may be a role for en face OCT in the detection of HCQ retinopathy. 
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